ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: biosimilars

FDA Approves First Biosimilar for the Treatment of Cancer

The U.S. Food and Drug Administration  |  September 14, 2017

Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment…

Filed under:Biologics/DMARDs Tagged with:Avastin (bevacizumab)biosimilar cancer drugCancerMvasi (bevacizumab-awwb)U.S. Food and Drug Administration

N.Y. Rheumatologist Makes Advocacy a Priority

Kelly Tyrrell  |  August 16, 2017

In 2005, not long after he became a private practice rheumatologist on Long Island, N.Y., Howard Blumstein, MD, dipped his toe into the advocacy pool at the encouragement of his partner, Max Hamburger, MD. “I thought it would be interesting to learn more about the issues that affect our patients and our practices, and I…

Filed under:Legislation & AdvocacyProfiles Tagged with:ACR’s Affiliate Society CouncilHoward BlumsteinNew York rheumatologist

Investments in Legislative Advocacy Pay Off for Ohio Association of Rheumatology

Gretchen Henkel  |  August 14, 2017

Like many other state rheumatology associations, the Ohio Association of Rheumatology (OAR) has recently been actively advocating for patient care at the state legislative level. The most recent example of OAR’s efforts included an Advocacy Day on May 4, when members met with state legislators to discuss topics of interest. It was the fourth such…

Filed under:Legislation & Advocacy Tagged with:Ohio Association of Rheumatology (OAR)step therapy

RISE Registry Data Now Available for Research Purposes

Sharad Lakhanpal, MBBS, MD  |  August 13, 2017

As medical professionals, we under­stand the impact quality research can have on how we care for our patients. The extensive adoption of electronic health records (EHRs) has enabled the collection of big data in rheumatology. This has provided a new and unique opportunity for the rheumatology community to conduct in-depth research into how patients are…

Filed under:EMRsPresident's PerspectiveTechnology Tagged with:datapatient carePractice ManagementrheumatologistrheumatologyRheumatology Informatics System for Effectiveness Registry

ACR Pushes for Patient Interests, Against Spending Cuts

Angus Worthing, MD, FACP, FACR  |  July 5, 2017

Greetings from Washington, D.C. Your advocacy team had another busy month. Unlike my prior updates, and in order to keep our focus on health policy, I avoid mentioning anything about Washington investigations into obstruction of justice, collusion, etc. You get enough of that elsewhere. The Healthcare Bill Obamacare repeal and reform efforts are speeding up….

Filed under:EULAR/OtherFrom the CollegeLegislation & AdvocacyMeeting ReportsProfessional Topics Tagged with:ACR advocacyAlliance for Transparent & Affordable Prescriptions (ATAP)alternative payment models (APMs)BiosimilarsEULARMedPacMIPSObamacare repealpharmacy benefit managers (PBMs)Washington D.C. update

Sanofi to Invest Further in Biologics

Matthias Blamont  |  June 14, 2017

PARIS (Reuters)—Sanofi announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics production, an area of strong growth potential. In contrast to most drugs that are chemically synthesized, many biologics are produced using living cells. They are seen as a promising answer in…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiologicsSanofi

Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

Susan Bernstein  |  June 14, 2017

While members of Congress debate healthcare legislation, rheumatologists say many of their patients struggle to afford everything from generic drugs to insurance copayments for physical therapy. “It’s a mess. The cost of prescriptions and the rationale for those rising costs in the U.S. right now—it’s just a mess,” says James R. O’Dell, MD, Stokes-Shackleford Professor of…

Filed under:Practice Support Tagged with:BiologicsBiosimilarsCompliancecostsdruggenericHealthcareMedicationpatient careRheumatic DiseaserheumatologistTreatment

U.S. Supreme Court Speeds Copycat Biologic Drugs to Market

Andrew Chung  |  June 13, 2017

WASHINGTON (Reuters)—The U.S. Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies. The justices, in a 9–0 ruling, overturned a lower court…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiologicsBiologics & BiosimilarsBiosimilarsLegalSupreme CourtU.S. Supreme Court

Fellows’ Forum: Why Rheumatology Fellows Should Get Involved with Advocacy

Alexandra Perel-Winkler, MD, & Christopher A. Mecoli, MD  |  May 16, 2017

Introduction Interest in rheumatology continues to grow, with more than 240 new adult and pediatric fellows to begin their training in the coming academic year. Given the broad and diverse career opportunities, it is an ACR goal to help guide trainees in their career decisions and professional development. Rheumatology fellowship often marks the transition from…

Filed under:Legislation & Advocacy Tagged with:AC&RAdvocacyAmerican College of Rheumatology (ACR)Capitol HillCongressEducationFellowsFellows ForumFundingLegislationpolicyrheumatologistRheumPAC

Step Therapy and Biosimilar Substitution Top the Priority List for the Rheumatology Association of Iowa

Kelly Tyrrell  |  May 3, 2017

A little more than three years ago, rheumatologist Michael Brooks, MD, FACP, FACR, Cedar Rapids, Iowa, turned years of discussion into something tangible: He and his colleagues got the paperwork and financial requirements in order and officially started the Rheumatology Association of Iowa. “We had been trying to get something going statewide in terms of…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:AdvocacyRheumatology Association of Iowa

  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 32
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences